Race Oncology’s Mr Phil Lynch (CEO & MD) and Dr Daniel Tillett (CSO & ED) presented to the MST Access Australian Micro & Small Caps Conference 2021 on the 17th June 2021.
Contract signed to support Race’s Phase 2 relapsed/refractory Acute Myeloid Leukemia (AML) trial at the Chaim Sheba Medical Center in Israel Trialog Clinical Trials Ltd to supply trial drugs and provide other clinical services Clinical trial contract is in final…
Race CEO/MD Phillip Lynch speaks to the Australia Shareholders Association about Race Oncology and our Three Pillar strategy to commercialise Bisantrene.
MST Access has initiated coverage of Race Oncology with a current $4.88 per share valuation. The full report can be downloaded below.
1 September 2020 – Race Oncology Limited (ASX: RAC) is pleased to announce that it has expanded its executive team with the appointment of Mr Phil Lynch as Chief Executive Officer and Managing Director. Effective immediately, Mr Lynch will share…
On 16 July 2020, Race was pleased to report results of the investigator led Phase II trial of bisantrene for relapsed or refractory Acute Myleoid Leukaemia. This post summarises the highlights and provides access to key resources related to the…
Race Oncology is pleased to announce that it has entered into a collaborative preclinical research program with The University of Newcastle. Eminent cancer researcher, Associate Professor Nikki Verrills of the Hunter Medical Research Institute, will lead the project. The aim…
Race has received firm commitments for A$1.8 million (before costs) in new equity funding via a strategic placement of six million ordinary shares, at an issue price of $0.30 per share. The placement has been anchored by biotechnology-focused institutional investor…
Race Oncology is pleased to welcome highly experienced oncology clinical trials specialist Dr Marinella Messina as its Australian Clinical Program Director. Dr Messina will commence of 16 March 2020 and will be responsible for progressing the Australian trials, part of…
Race Oncology Limited is pleased to announce that Professor Borje Andersson has been appointed to the Board as a Non-Executive Director. Prof Andersson is an internationally acclaimed leader in the fields of leukaemia and stem cell transplant research at MD…
